Clinical and serological characteristics of 125 Dutch myositis patients - Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies

被引:83
作者
Hengstman, GJD
Brouwer, R
Egberts, WTMV
Seelig, HP
Jongen, PJH
van Venrooij, WJ
van Engelen, BGM
机构
[1] Univ Nijmegen, Med Ctr, Inst Neurol, Neuromuscular Ctr Nijmegen, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands
[3] Inst Immunol & Mol Genet, Karlsruhe, Germany
关键词
myositis; autoantibody; serology; antibody;
D O I
10.1007/PL00007850
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic diseases that include the familiar disease entities of dermatomyositis (DM), polymyositis (PM), and inclusion body myositis (IBM). A subset of patients has unique autoantibodies which are specific for IIM (myositis specific autoantibodies; MSAs). We studied the clinical and serological characteristics of IIM in 125 Dutch patients. Sera were analysed by immunoblotting, enzyme-linked immunosorbent assay, and immunoprecipitation. The most frequently encountered MSA was the anti-Jo-1 autoantibody (20%), followed by anti-tRNA(His) (6%), anti-Mi-2 (6%), and anti-SRP (4%). The presence of certain MSAs was clearly associated with specific clinical characteristics. Anti-Jo-1 and anti-tRNA(His) were associated with the anti-synthetase syndrome, anti-SRP with PM with severe myalgia and arthralgia and a moderate response to immunosuppressive treatment. A novel finding was the presence of anti-Mi-2, not only in DM, but also in PM. MSAs were frequently present in DM/PM sera, but were hardly ever detected in the sera of IBM patients. The few IBM patients with MSAs demonstrated a significant response to immuno suppressive treatment. It can be concluded that MSAs define specific clinical syndromes within the spectrum of IIM and that they can assist in the differential diagnosis and treatment plan of these enigmatic disorders by virtually excluding IBM by their presence, and by potentially identifying a subgroup of steroid-responsive IBM patients.
引用
收藏
页码:69 / 75
页数:7
相关论文
共 28 条
[1]
Inclusion body myositis: Clinical and pathological boundaries [J].
Amato, AA ;
Gronseth, GS ;
Jackson, CE ;
Wolfe, GI ;
Katz, JS ;
Bryan, WW ;
Barohn, RJ .
ANNALS OF NEUROLOGY, 1996, 40 (04) :581-586
[2]
Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis [J].
Arnett, FC ;
Targoff, IN ;
Mimori, T ;
Goldstein, R ;
Warner, NB ;
Reveille, JD .
ARTHRITIS AND RHEUMATISM, 1996, 39 (09) :1507-1518
[3]
POLYMYOSITIS AND DERMATOMYOSITIS .1. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) :344-347
[4]
Brouwer R, 1998, ARTHRITIS RHEUM, V41, P1428, DOI 10.1002/1529-0131(199808)41:8<1428::AID-ART12>3.0.CO
[5]
2-J
[6]
AUTOANTIBODIES AGAINST ALANYL-TRANSFER RNA-SYNTHETASE AND TRANSFER RNAALA COEXIST AND ARE ASSOCIATED WITH MYOSITIS [J].
BUNN, CC ;
BERNSTEIN, RM ;
MATHEWS, MB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (05) :1281-1291
[7]
CRONIN ME, 1988, PRIMER RHEUMATIC DIS, P120
[8]
POLYMYOSITIS, DERMATOMYOSITIS, AND INCLUSION-BODY MYOSITIS [J].
DALAKAS, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (21) :1487-1498
[9]
DALAKAS MC, 1995, ANN NEUROL, V37, P74
[10]
ENGEL AG, 1994, MYOLOGY, P1335